聚乙二醇化蛋白质市场：按类型、按蛋白质、按应用、按最终用户、按（地区）、规模、份额、展望、机会分析，2022-2030 年

聚乙二醇化是将活性聚乙二醇 (PEG) 添加到各种形式的治疗性蛋白质中以对其进行化学修饰的过程。 这些经过化学修饰的治疗性蛋白质被称为聚乙二醇化蛋白质治疗剂。 聚乙二醇化蛋白质疗法用于多种疾病，包括癌症、血友病、类风湿性关节炎、强直性脊柱炎和克罗恩氏病。 聚乙二醇化是一个术语，描述了用聚乙二醇 (PEG)（一种无毒、非免疫原性聚合物）对生物分子进行共价修饰，以减少生物药物的缺点。

聚乙二醇 (PEG) 因其“静音”特性和生物相容性声明而经常用于药物输送和纳米技术。 人们普遍认为聚乙二醇化允许生物材料和颗粒递送方法逃避免疫系统并延长循环寿命。 然而，蛋白质的聚乙二醇化是一个复杂的过程，可以使用多种方法进行，具体取决于蛋白质类型和应用。 惰性 PEG 串共价或非共价结合到感兴趣的蛋白质。 另一个关键步骤是聚乙二醇化蛋白质的纯化，这主要通过层析和静电相互作用或分子大小来实现。

市场动态

市场主要参与者越来越多地采用无机策略，例如产品发布，预计将在预测期内推动市场增长。 例如，诺和诺德公司于2020年2月在美国推出的用于治疗A型血友病患者的ESPEROCT，用于预防或减少出血事件、治疗和控制出血、重组半衰期延长因子VIII替代疗法、抗血友病因子（重组），聚乙二醇化-EXei，用于控制出血。

这项研究的主要特点

• 本报告对全球聚乙二醇化蛋白质市场进行了深入分析，提供了以 2021 年为基准年的预测期 (2022-2030) 的市场规模和復合年增长率 (CAGR%) 增长情况。
• 解释了不同细分市场的潜在创收机会，并描述了针对该市场的有吸引力的投资建议矩阵。
• 它还提供了有关市场驱动因素、制约因素、机会、新产品发布和批准、市场趋势、区域前景以及主要参与者采用的竞争战略的重要见解。
• 它根据以下参数提供了全球聚乙二醇化蛋白质市场主要参与者的概况 - 公司亮点、产品组合、主要亮点、财务业绩和战略。
• 本研究涵盖的主要公司包括 Biogen Inc、Pfizer Inc、UCB S.A.、Leadiant Biosciences, Inc.、Amgen Inc.、Thermo Fisher Scientific Inc.、Horizo□□n Therapeutics Plc.、Novo Nordisk A/S、F。 Hoffmann-La Roche AG、Bayer AG、BioMarin、RedHill Biopharma Ltd.
• 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
• 全球聚乙二醇化蛋白质市场报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者将可以通过用于分析全球聚乙二醇化蛋白质市场的各种战略矩阵轻鬆做出决策。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第2章市场展望

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场概况：按类型分类
  • 市场概况：按蛋白质分类
  • 市场概况，按应用分类
  • 市场概况：按最终用户分类
  • 市场概况：按地区
• 连贯机会图 (COM)

第3章市场动态、规律及趋势分析

• 市场动态
  • 司机
  • 约束因素
  • 市场机会
• 影响分析
• 市场趋势
• 近期趋势
• 收购和合作场景
• 技术概述
• 监管场景
• 管道分析
• 害虫分析

第 4 章聚乙二醇化蛋白质的全球市场：冠状病毒 (COVID-19) 大流行的影响

• 总体影响
• 对供需的影响
• COVID-19 对市场的影响

第 5 章聚乙二醇化蛋白质的全球市场：按类型，2017-2030

• 消耗品
• 服务

第 6 章聚乙二醇化蛋白质的全球市场：按蛋白质分类，2017-2030

• 集落刺激因子
• 干扰素
• 促红细胞生成素
• 重组因子 VIII
• 其他

第 7 章聚乙二醇化蛋白质的全球市场：按应用分类，2017-2030

• 癌症
• 自身免疫性疾病
• 肝炎
• 多发性硬化症
• 血友病
• 消化系统疾病
• 其他

第 8 章聚乙二醇化蛋白质的全球市场：按最终用户分类，2017-2030

• 製药和生物技术公司
• 委託研究机构
• 学术研究所

第 9 章按地区划分的聚乙二醇化蛋白质全球市场，2017-2030

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 意大利
• 法国
• 西班牙
• 俄罗斯
• 其他欧洲地区
• 亚太地区
• 中国
• 印度
• 日本
• 东盟
• 澳大利亚
• 韩国
• 其他亚太地区
• 中东
• 海湾合作委员会
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中非
• 南非

第10章竞争格局

• Biogen Inc.
• Pfizer Inc.
• UCB S.A.
• Leadiant Biosciences, Inc.
• Amgen Inc.
• Thermo Fisher Scientific Inc.
• Horizon Therapeutics Plc.
• Novo Nordisk A/S
• F. Hoffmann-La Roche AG
• Bayer AG
• BioMarin
• RedHill Biopharma Ltd

第 11 章章节

• 调查方法
• 关于出版商

PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. PEGylated protein therapeutics are used in multiple conditions, such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and others. PEGylation is the term used to describe the covalent modification of biological molecules with the non-toxic, non-immunogenic polymer polyethylene glycol (PEG) in order to reduce the drawbacks of some biopharmaceuticals.

Due to its claimed "silent" qualities and biocompatibility, polyethylene glycol (PEG) is frequently used in medication delivery and nanotechnology. It is commonly accepted that PEGylation enables biomaterials and particle delivery methods to sidestep the immune system and extend circulation lifetimes. Nevertheless, PEGylation of proteins is a complicated procedure that can be completed using a variety of methods, depending on the type of the protein and the intended application. Inert PEG strings are covalently or non-covalently complexed with proteins of interest. Another crucial step is the purification of the PEGylated protein, which is mostly accomplished through chromatography and electrostatic interactions or molecular sizes.

Market Dynamics

Increasing adoption of inorganic strategies by key players in market such as product launch is expected to drive market growth over the forecast period. For instance, in February 2020, the Novo Nordisk launched ESPEROCT in the U.S. for the treatment of people with hemophilia A. It is a recombinant extended half-life factor VIII replacement therapy used to prevent or reduce the number of bleeding episodes, to treat and control bleeding, and to manage bleeding during surgery in people with hemophilia A. ESPEROCT is antihemophilic factor (recombinant), glycopegylated-exei.

Key features of the study:

• This report provides an in-depth analysis of the global PEGylated proteins market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global PEGylated proteins market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biogen Inc, Pfizer Inc, UCB S.A., Leadiant Biosciences, Inc., Amgen Inc., Thermo Fisher Scientific Inc., Horizon Therapeutics Plc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, BioMarin, RedHill Biopharma Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global PEGylated proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PEGylated proteins market

Detailed Segmentation:

• Global PEGylated Proteins Market, By Type:
  • Consumables
  • Services
• Global PEGylated Proteins Market, By Protein:
  • Colony-stimulating factor
  • Interferons
  • Erythropoietin
  • Recombinant factor VII
  • Other
• Global PEGylated Proteins Market, By Application:
  • Cancer
  • Autoimmune Disease
  • Hepatitis
  • Multiple Sclerosis
  • Hemophilia
  • Gastrointestinal Disorder
  • Others
• Global PEGylated Proteins Market, By End User:
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Academic Research Institutes
• Global PEGylated Proteins Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Biogen Inc, Pfizer Inc
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Pfizer Inc
  • UCB S.A.
  • Leadiant Biosciences, Inc.,
  • Amgen Inc.
  • Thermo Fisher Scientific Inc.
  • Horizon Therapeutics Plc.
  • Novo Nordisk A/S
  • Hoffmann-La Roche AG
  • Bayer AG
  • BioMarin
  • RedHill Biopharma Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Protein
  • Market Snapshot, By Application
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• Pipeline Analysis
• PEST Analysis

4. Global PEGylated Proteins Market- Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• Impact on Supply and Demand
• COVID-19 Impact on the market

5. Global PEGylated Proteins Market, By Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Consumables
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others
• Services
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global PEGylated Proteins Market, By Protein, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Colony Stimulating Factor
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others
• Interferon
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Erythropoietin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Recombinant Factor VIII
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global PEGylated Proteins Market, By Application, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Autoimmune Disease
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Hepatitis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Multiple Sclerosis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Hemophilia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Gastrointestinal Disorder
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global PEGylated Proteins Market, By End User, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Pharmaceutical and Biotechnology Companies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Contract Research Organizations
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Academic Research Institutes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

9. Global PEGylated Proteins Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Protein, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Protein, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Protein, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Protein, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Protein, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Protein, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Biogen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• UCB S.A.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Leadiant Biosciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Thermo Fisher Scientific Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Horizon Therapeutics Plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novo Nordisk A/S
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F. Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• BioMarin
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• RedHill Biopharma Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

11. Section

• Research Methodology
• About Us